fbpx
Connect with us

BUSINESS

PotNetwork Holdings Inc (OTCMKTS:POTN) Is All Set for Form 10 Filing with SEC

Published

on

The board of directors of PotNetwork Holdings Inc (OTCMKTS:POTN) has decided for form 10 filing with SEC (Securities and Exchange Commission) in order to become a fully reporting company. The proposed action improves transparency to the investors. It also improves credibility and visibility to a large number of qualified investors. The filing process will be completed before June 30, 2018.

PotNetwork Holdings Inc Announces Audited Financial Statements

PotNetwork Holdings Inc has reported revenues of $14.49 million for the year 2017. Its gross profits are estimated at $5,180,865.

Chief Executive Officer of PotNetwork Holdings Inc., Richard Goulding said the company deserves a strong presence in the financial markets with a strongly focused business model. The company is demonstrating strong gains year on year and expanding its distribution efforts. It is all set to announce significant developments next year and hence the need for form 10 filing.

Diamond CBD, Inc., a subsidiary of PotNetwork Holdings Inc., Surpasses Monthly Sales of     $2 Million

Diamond CBD, Inc. has reported revenues of more than $2 million. It is continuing the trend of reporting a significant increase in sales year on year.

The company has generated sales of more than half a million dollar through online in the first 27 days of May 2018. It has shown a commendable performance when compared to the same period in 2017. It is mainly due to the company’s ability to scale up production and create new products to meet the growing needs of the customers.

Brief Information about PotNetwork Holdings Inc

PotNetwork Holdings Inc was established in the year 2004. It focuses on marijuana market. The company conducts its business operations through its wholly owned subsidiaries such as First Capital Venture Co., and Sunrise Auto Mall Inc. It also owns another subsidiary Diamond CBD Inc.

Brief Information about Diamond CBD Inc

Diamond CBD Inc is engaged in R&D and multinational sales of premium hemp extracts. Its hemp extracts consist of natural hemp derivatives and cannabinoids. The company has employed natural product experts, hemp industry pioneers, scientists, doctors, and chemists. The company is dedicated to producing pure and finest CBD oils.

BUSINESS

Real Brands Inc (OTCMKTS:RLBD) Signs An LOI To Purchase Proprietary CBD Formulas From Florida Based Integrative Medicine US

Published

on

Real Brands Inc (OTCMKTS:RLBD) has signed an LOI to buy proprietary CBD formulas of Integrative Medicine US. The formulas comprise ancient Chinese Medicine and Herbal Remedies that are blended CBD, nutrients, and endocannabinoid systems. Following the acquisition, Real Brands will use the formulas in its CBD Pharmacy brand. The company will use the new logo with a Chinese Symbol of healing.

CBD Pharmacy products

The initial product launch of CBD Pharmacy comprise salves, tinctures, balms, powders, and capsules developed to treat pain and promote relaxation, and boost immunity and energy.

Jerry Pearring, Chief Executive Officer of Real Brands, said medicinal herbs, CBD, and vitamins are blended using a proprietary formula to develop innovative medicine by Jonathan M. Fields, the founder of Integrative Medicine. The new products will help to keep the Real Brands in the driver’s seat to create a strong brand for CBD Pharmacy.

According to Pearring, CBD Pharmacy is expected to satisfy the growing consumer demand for hemp derived cannabidiol products. Consumers will also enjoy the benefits of eastern medical therapies.

Jonathan said the recent technological advances helped the company to develop superior medicinal products. Its features include Vegan, 100% Non-GMO, and tested in a third-party lab using cannabidiol. The company developed delivery mechanisms so that customers can get CBD and other ingredients in the right dosage to provide the desired effect for long-time.

Partners with Scot Piercy

Real Brands has partnered with Scot Piercy, a professional athlete, in April 2019. He will act as an ambassador for Real Brands Team and invested in the company last month. Pearring commenting the partnership said the company is excited to announce Scot as an ambassador. The investment shows the belief in the business model of the company and the long-term prospects. Pearring is pleased to welcome Scot on board Real Brands.

Piercy said he is proud to join the team of Real Brands. He studied about Real Brands and provides the support to grow hemp derived cannabidiol brands. Piercy further said it is looking forward to work with the company to introduce unique brands of Real Brands through e-commerce sites and retail channels.

Continue Reading

BUSINESS

Hexo Corp (NYSEAMERICAN:HEXO) Acquisition Of Newstrike Brands Finalized

Published

on

Acquisition now Finalized

Hexo Corp (NYSEAMERICAN:HEXO) has announced that it has completed the acquisition of all of Newstrike Brands’ issued and outstanding securities totaling 558,971, 064 marking the finalization of the acquisition process. The company has also received regulatory approval from relevant authorities including the high court further stamping the deal.

Reportedly, Newstrike Brands’ board of directors voted enthusiastically in favor of the acquisition that saw each of Newstrike’s stock exchanged for 0.06332 of Hexo’s share. Following the completion of the acquisition process, is expected to be delisted from TSX exchange platform as it will now operate under its new owner- Hexo.

Increased Production Space and Capacity

Popular voices in the industry believe that the $263 million acquisition sets Hexo among the industry’s elite. Among the several befits Hexo stands to gain from the acquisition includes additional production space estimated at 470,000 sqft. This is a significant addition to the company’s existing 1.3 million sqft.

With additional growing space comes increased production capacity. It is estimated that Hexo’s annual production capacity will surge from the current 110,000 kilos annually to a whopping 150,000 kilos annually which obviously translates to revenue influx.

Hexo’s CEO, Sebastien St-Louis said that “The combination of these two talented teams, both pioneers in the cannabis industry, will accelerate Hexo’s vision of creating the best cannabis technology company.” He adds that the Hexo is now commencing journey on the next phase of its progress.

The acquisition enhances the company’s solid position in the Canadian cannabis space and opening it up to countless possibilities abroad. The company already announced plans to set up operation in Greece as it seeks to seize the upcoming European market. Plans are also underway to set up operations in South America, the U.S (which is expected to open up fully by 2020), and more other locations.

The company already adjusted its 2020 revenue outlook to an optimistic $400 million. This projection factors in the company’s now bigger size in terms of production capacity and market access considering Hexo now assumes Newstrike’s distribution agreements with strategic partners across 8 Canadian provinces.

Continue Reading

BUSINESS

Synthetic MMJ Versus the Real Stuff

Published

on

CBD

When we use the term medical marijuana, we are referring to the entire unprocessed cannabis plant or its extracts for use as a pharmacological input in a treatment regime for individuals suffering from a variety of different health conditions. It may interest you to know that medical marijuana, at this point, only has explicit FDA approval as a safe and effective treatment for two conditions, both of which are severe and rare forms of epilepsy. Both of these conditions involve severe seizures and both of them represent conditions that no other pharmaceutical solution has been able to treat.

The established pharmaceutical version of medical marijuana that is used to treat these conditions is known as Epidiolex. This medication contains a pure form of CBD, and the FDA gave this approval in June 2018. Note it is also important to understand that the FDA has approved medications containing a synthetic version of THC known as Marinol and Cesamet. These drugs are used to treat nausea in people who are undergoing treatments for cancer and HIV. Interestingly, the FDA has not approved any marijuana-based drugs for the treatment of chronic or acute pain.

Synthetic versions of marijuana are often referred to as “Spice” or “K2”. According to the National Institute on drug abuse, synthetic marijuana is not considered marijuana. It is also not considered safe and is not recommended for any purpose. The important point to understand here is that synthetic marijuana attempts through chemical means to reproduce the essential function of marijuana as it interacts with human physiology. This runs up against what is known as the entourage effect – the idea that all of the elements of the cannabis plant work together in ways that supersede the impacts of just CBD or THC working alone.

Seen from this perspective, synthetic marijuana may not be nearly as effective and may have additional side effects that are difficult to account for.

Continue Reading
Advertisement
Advertisement
Advertisement






Trending Stories